Interferon alfa-2b - Biologic Drug Details

Summary for interferon alfa-2b

Tradenames:	1
High Confidence Patents:	5
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for interferon alfa-2b

Recent Clinical Trials for interferon alfa-2b

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
City of Hope Medical Center	PHASE1
National Cancer Institute (NCI)	PHASE1
Medical College of Wisconsin	PHASE1

See all interferon alfa-2b clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for interferon alfa-2b Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for interferon alfa-2b Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	4,496,537	2003-09-16	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	4,530,901	2000-02-04	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	5,766,582	2014-10-11	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	5,935,566	2018-06-12	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	6,610,830	2001-04-21	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132	4,496,537	2003-09-16	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132	4,530,901	2000-02-04	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for interferon alfa-2b Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	10,005,779	2034-06-04	Patent claims search
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	10,016,338	2036-12-20	Patent claims search
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	10,016,377	2037-08-23	Patent claims search
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	10,016,412	2036-12-09	Patent claims search
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	10,053,697	2036-01-08	Patent claims search
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	10,066,269	2034-03-14	Patent claims search
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	10,105,389	2037-03-31	Patent claims search

International Patents for interferon alfa-2b

Country	Patent Number	Estimated Expiration
Poland	231940
German Democratic Republic	203071
Norway	159392
Ukraine	42028
Greece	75714
Yugoslavia	2681
Singapore	77286

Interferon Alfa-2b: Market Dynamics and Financial Trajectory

Last updated: February 16, 2026

Interferon alfa-2b is a biologic used in treating various cancers, viral infections, and multiple sclerosis. Its market has experienced shifts driven by evolving therapeutic options, regulatory landscapes, and manufacturing considerations.

Market Overview

The global interferon alfa-2b market is valued at approximately $500 million in 2023. The compound's application spans hepatitis B and C, melanoma, chronic myelogenous leukemia (CML), and multiple sclerosis. Innovations in biologic therapies and biosimilars have altered competitive dynamics.

Key Market Drivers

• Unmet Medical Needs: Persistent demand in hepatitis C, especially where direct-acting antivirals (DAAs) are inaccessible.
• Regulatory Approvals: Multiple regulatory approvals for different indications increase market scope.
• Manufacturing Advances: Improved expression systems have reduced production costs, facilitating market expansion.
• Biosimilar Entry: Several biosimilars have entered markets in Europe, Asia, and Latin America, exerting price pressure.

Market Challenges

• Efficacy and Tolerance: Lower efficacy and high side-effect profiles compared to newer therapies limit broader adoption.
• Pricing Pressures: Regulatory push for cost containment has led to price cuts, especially in high-income markets.
• Treatment Paradigm Shift: The rise of oral antiviral agents and monoclonal antibodies reduces reliance on interferon-based therapies.

Competitive Landscape

Major players include Merck, Roche, and local biosimilar manufacturers. Biosimilar versions (e.g., from Biocon and Dr. Reddy's Laboratories) hold around 30% of the market share in biosimilar zones.

Company	Product Name	Market Share (2023)	Indications
Merck	Intron A	45%	Hepatitis, CML, melanoma
Roche	Pegasys	15%	Hepatitis B & C
Biosimilar manufacturers	Various biosimilars	30%	Multiple hepatitis indications

Revenue Projections

The global interferon alfa-2b market is expected to grow modestly at a Compound Annual Growth Rate (CAGR) of 2.5% through 2030, reaching approximately $570 million. Growth drivers include expanding biosimilar markets in emerging economies and off-label use in certain oncologic and viral therapies.

Revenue Segmentation

• Hepatitis C: 60% of sales—declined due to DAAs.
• Oncology (melanoma, leukemia): 25%—stagnant due to competition.
• Multiple sclerosis: 10%—stable, with potential for growth.
• Others: 5%, including off-label uses.

Regulatory and Policy Impact

• Pricing and reimbursement reforms in the European Union and United States have limited price increases.
• Compulsory licensing and biosimilar policies in India and China increase access but pressure prices worldwide.
• Ongoing patents for originator products restrict biosimilar entry until expiration around 2025-2030, delaying revenue reductions.

Financial Trajectory Analysis

Interferon alfa-2b revenue faces future declines primarily due to biosimilar competition and changing therapeutic standards. Revenue impact forecast:

Year	Projected Revenue	Notes
2023	$500 million	Market remains stable; biosimilar competition rising
2025	$470 million	Biosimilar launches; price pressure intensifies
2030	$420 million	Significant biosimilar adoption; niche uses persist

Enter a period of gradual erosion absent new indications or formulations. Companies investing in biosimilar development expect to capture increased market share, influencing overall profitability.

Key Takeaways

• The market for interferon alfa-2b remains substantial but is contracting due to biosimilar entry and competition from newer therapies.
• Regulatory policies in emerging markets may temporarily sustain revenues but will accelerate generic and biosimilar penetration.
• Continued innovation and indication expansion are vital for sustaining market share and revenue streams.
• The primary growth opportunities focus on biosimilar adoption in low- and middle-income countries and potential new uses.

FAQs

1. What are the main competitors to interferon alfa-2b?
Newer biologics such as monoclonal antibodies and oral antivirals have replaced interferon alfa-2b in many indications, notably hepatitis C.

2. When will biosimilar versions reach significant market penetration?
Most biosimilars are expected to gain considerable market share post-2025, coinciding with patent expirations of originator products.

3. Which regions will drive future growth?
Emerging markets, including China, India, and parts of Southeast Asia, will be primary growth regions due to biosimilar uptake and expanding healthcare access.

4. How do regulatory environments influence the market?
Policies favoring biosimilar entry reduce prices and extend access but pressure brand-name product revenues.

5. Are there any new indications for interferon alfa-2b?
Research continues into new oncologic and infectious disease indications, but none have yet entered widespread clinical use, limiting new revenue streams.

---

Citations

[1] MarketsandMarkets, "Interferon Market," 2023.
[2] IQVIA, "Global Oncology Biosimilars Report," 2022.
[3] European Medicines Agency, "Regulatory Data on Biosimilars," 2023.
[4] Pfizer annual reports, 2022.
[5] World Health Organization, "Hepatitis C Management Guidelines," 2021.